Pipeline-Prospector-Insert
X

Find drug development pipeline and deal Updates information

A collaboration with SCORR Marketing

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter
            refresh

            Product Type

            Companies

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Ruxolitinib

            Therapeutic Area: Dermatology

            Highest Development Status: Phase III Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable January 28, 2020

            Details:

            The study was testing the ruxolitinib cream in adolescent and adult patients aged 12 years and above.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Baricitinib, Corticosteroid

            Therapeutic Area: Dermatology

            Highest Development Status: Phase III Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable January 27, 2020

            Details:

            Study met primary endpoint of at least 75% improvement of skin inflammation. Safety profile was consistent with the known safety findings of baricitinib in atopic dermatitis.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Prabotulinumtoxin A

            Therapeutic Area: Dermatology

            Highest Development Status: Phase III Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable January 27, 2020

            Details:

            Primary endpoint of non-Inferiority achieved with responder rates* of 65.02% for PrabotulinumtoxinA and 62.56% for OnabotulinumtoxinA at week 4.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Tapinarof

            Therapeutic Area: Dermatology

            Highest Development Status: Phase III Product Type: Small molecule

            Partner/Sponsor/Collaborator: Japan Tobacco

            Deal Size: $113.0 million Upfront Cash: $60.0 million

            Deal Type: Licensing Agreement January 15, 2020

            Details:

            A license agreement to develop, register and market tapinarof in Japan for the treatment of dermatological diseases and conditions, including psoriasis and atopic dermatitis.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): EB-101

            Therapeutic Area: Dermatology

            Highest Development Status: Phase III Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable January 13, 2020

            Details:

            Many patients selected for registration have completed the Stanford pre-screening process, and the Company expects to treat the first patient in the VIITALTM trial in the first quarter of 2020.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Risankizumab

            Therapeutic Area: Dermatology

            Highest Development Status: Phase III Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable January 13, 2020

            Details:

            SKYRIZI™ (risankizumab) met both primary and all secondary endpoints in a head-to-head, open-label study versus Cosentyx® (secukinumab).

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Sofpironium bromide

            Therapeutic Area: Dermatology

            Highest Development Status: Phase III Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable January 10, 2020

            Details:

            The application for sofpironium bromide in Japan involves data from the Phase 3 study in Japan, targeting patients with primary axillary hyperhidrosis, in which positive results were obtained.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Lebrikizumab

            Therapeutic Area: Dermatology

            Highest Development Status: Phase III Product Type: Large molecule

            Partner/Sponsor/Collaborator: Eli Lilly and Company

            Deal Size: $1,100.0 million Upfront Cash: $1,100.0 million

            Deal Type: Acquisition January 10, 2020

            Details:

            Lilly gets Dermira’s experimental treatment for atopic dermatitis, as well as an approved medicated cloth for excessive armpit sweating.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Berdazimer sodium

            Therapeutic Area: Dermatology

            Highest Development Status: Phase III Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable January 02, 2020

            Details:

            Statistical significance was not achieved for the primary endpoint in either B-SIMPLE1 or B-SIMPLE2, however multiple sensitivity analyses are supportive of a potential path forward for the asset.